Single peptide ligand-functionalized uniform hollow mesoporous silica nanoparticles achieving dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells.

Abstract

BACKGROUND:

The purpose of this study was to construct hollow mesoporous silica nanoparticles (HMSN) decorated with tLyp-1 peptide (tHMSN) for dual-targeting drug delivery to tumor cells and angiogenic blood vessel cells.

METHODS:

HMSN were synthesized de novo using a novel cationic surfactant-assisted selective etching strategy and were then modified with tLyp-1. Multiple methods, including transmission electron microscopy, X-ray photoelectron spectroscopy, thermogravimetric analysis, bicinchoninic acid assay, and nitrogen adsorption and desorption isotherms, were used to characterize the tHMSN. Doxorubicin were chosen as the model cargo, and the uptake of doxorubicin-loaded tHMSN into MDA-MB-231 cells and human umbilical vein endothelial cells (HUVECs), as models of tumor cells and tumor neovascular endothelial cells, respectively, were observed and detected by confocal laser scanning microscopy and flow cytometry. An in vitro pharmacodynamic study and a study of the mechanism via which the nanoparticles were endocytosed were also performed.

RESULTS:

HMSN with a highly uniform size and well oriented mesopores were synthesized. After tHMSN were characterized, enhanced uptake of the cargo carried by tHMSN into MDA-MB-231 cells and HUVECs compared with that of their unmodified counterparts was validated by confocal laser scanning microscopy and flow cytometry at the qualitative and quantitative levels, respectively. Further, the pharmacodynamic study suggested that, compared with their unmodified counterparts, doxorubicin-loaded tHMSN had an enhanced inhibitory effect on MDA-MB-231 cells and HUVECs in vitro. Finally, a preliminary study on the mechanism by which the nanoparticles were endocytosed indicated that the clathrin-mediated endocytosis pathway has a primary role in the transport of tHMSN into the cytoplasm.

CONCLUSION:

tHMSN might serve as an effective active targeting nanocarrier strategy for anti-mammary cancer drug delivery.

• Authors: Yang Liu, Qing Chen, Ming Xu, Guannan Guan, Wen Hu, Ying Liang, Xiuli Zhao, Mingxi Qiao, Dawei Chen, Hao Liu
• Journal: International journal of nanomedicine (Int J Nanomedicine) Vol. 10 Pg. 1855-67 ( 2015) ISSN: 1178-2013 [Electronic] New Zealand
• PMID: 25834425 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibiotics, Antineoplastic
• Drug Carriers
• Ligands
• Peptides
• Silicon Dioxide
• Doxorubicin

Topics

• Antibiotics, Antineoplastic (administration & dosage)
• Cell Line, Tumor (drug effects)
• Clothing
• Doxorubicin (administration & dosage, chemistry)
• Drug Carriers (administration & dosage, pharmacokinetics)
• Drug Delivery Systems (methods)
• Endocytosis
• Human Umbilical Vein Endothelial Cells (drug effects)
• Humans
• Ligands
• Microscopy, Electron, Transmission
• Nanoparticles (administration & dosage, chemistry, toxicity)
• Neovascularization, Pathologic (drug therapy, pathology)
• Peptides (chemistry)
• Photoelectron Spectroscopy
• Silicon Dioxide (chemistry)
• Thermogravimetry